Original Article •International Open Medical Journal. 1(1):e202503

Association of Immune-Related Adverse Events with Efficacy in Patients With Small Cell Lung Cancer: a Second Analysis of Phase 3 IMpower133 Randomized Clinical Trials

Sinbad

1.Department of Respiratory Disease, Zhejiang University, School of Medicine, The First Affiliated Hospital, Hangzhou, China.

Background

Immune-related adverse events (irAEs) have been found to predict PD-L1 inhibitor efficacy in metastatic NSCLC. However, the relation of irAEs to clinical outcome for SCLC has remained unknown.

Methods

Individual participant data from randomized phase Impower133 (ClinicalTrials.gov identifier: NCT02763579) was utilized for this post-hoc analysis. To evaluate the association between irAEs and efficacy in patients with small cell lung cancer (SCLC) using Impower 133 study.

Results

We assessed the association between irAE and overall survival (OS) in IMpower 133 study, irAE showed a slight increased risk of death (10 vs 9.77 months) versus patients without irAE.

Conclusions

In Impower133 randomized clinical trials, longer slightly OS was observed in irAE patients. The irAEs might is not a prognosis to predict a better survival outcome in SCLC, further studies need to explore the prognosis in SCLC.

Reference:

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

Acknowledgement 

This presentation based on research using data from data contributors Roche that has been made available through Vivli, Inc. Vivli has not contributed to or approved, and is not in any way responsible for, the contents of this publication.

• Publication Dates
•  Publication in this collection
• • 07 July 2025
  •  Date of issue
    2025
  • History
  • Received 5 May 2025
  •  Accepted 10 June 2025